293 related articles for article (PubMed ID: 35077347)
21. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Di Dalmazi G; Ippolito S; Lupi I; Caturegli P
Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671
[No Abstract] [Full Text] [Related]
22. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
23. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
24. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
Fujita Y; Kamitani F; Yamamoto M; Fukuoka H; Hirota Y; Nishiyama N; Goda N; Okada Y; Inaba Y; Nakajima H; Kurematsu Y; Kanie K; Shichi H; Urai S; Suzuki M; Yamamoto N; Bando H; Iguchi G; Suto H; Funakoshi Y; Kiyota N; Takahashi Y; Ogawa W
J Endocr Soc; 2023 Jan; 7(3):bvad002. PubMed ID: 36694808
[TBL] [Abstract][Full Text] [Related]
25. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
26. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
[TBL] [Abstract][Full Text] [Related]
27. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
Atkinson M; Lansdown AJ
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
[TBL] [Abstract][Full Text] [Related]
28. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
29. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
Fukuda I
J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
[TBL] [Abstract][Full Text] [Related]
31. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
32. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract][Full Text] [Related]
33. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIES.
Pollack R; Kagan M; Dresner-Pollak R; Neuman T
Endocr Pract; 2021 Jan; 27(1):34-37. PubMed ID: 33475499
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
36. Endocrine side effects of immune checkpoint inhibitors.
Cardona Z; Sosman JA; Chandra S; Huang W
Front Endocrinol (Lausanne); 2023; 14():1157805. PubMed ID: 37251665
[TBL] [Abstract][Full Text] [Related]
37. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
38. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
[TBL] [Abstract][Full Text] [Related]
40. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
